Assessing the commercial potential of an asset in Tourette’s Syndrome
Less than 1 min read
Scroll
SmartAnalyst was set the task to evaluate the commercial opportunity for a potential asset in Tourette’s Syndrome.
SmartAnalyst conducted both primary and secondary research to develop a future disease landscape, a Target Product Profile (TPP) and revenue forecast.
SmartAnalyst demonstrated the potential of the asset through scenario evaluation and the impact on revenue and valuation..
Read the full case study here.
Jump to a slide with the slide dots.
Assessing the commercial opportunity for a new CAR-T therapy
Read how we assessed the commercial opportunity for a new CAR-T therapy.
Read moreAssessing the commercial potential of an asset in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Making informed clinical and commercial decisions can help to optimize the value of an asset for pharmaceutical companies.
Read more